Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.37 |
| ▸ | IKBKB | O14920 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211412 | 1.00 | NR4A2 (0.37) | NR4A2IKBKBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL621478 | 0.89 | GABRA1 (0.41) | IKBKBALDH1A1SMN1; SMN2L3MBTL1OPRK1 | |
| SCHEMBL619495 | 0.89 | IKBKB (0.40) | IKBKBALDH1A1SMN1; SMN2L3MBTL1CHUK | |
| SCHEMBL618368 | 0.85 | NR4A2 (0.41) | NR4A2IKBKBOPRK1PDK2PDK4 | |
| SCHEMBL621251 | 0.83 | NR4A2 (0.40) | NR4A2IKBKBALDH1A1L3MBTL1OPRK1 | |
| SCHEMBL621159 | 0.81 | NR4A2 (0.39) | NR4A2IKBKBOPRK1PDK2PDK4 | |
| SCHEMBL10211413 | 0.81 | IKBKB (0.57) | NR4A2IKBKBOPRK1PDK2PDK4 | |
| SCHEMBL621124 | 0.74 | GABRA1 (0.42) | IKBKBALDH1A1SMN1; SMN2OPRK1CHUK | |
| SCHEMBL10211391 | 0.72 | IKBKB (0.38) | IKBKBALDH1A1CHUK | |
| SCHEMBL622105 | 0.72 | GABRA1 (0.41) | IKBKBALDH1A1SMN1; SMN2OPRK1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
| EP-2139322-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | Smithkline Beecham Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008118724-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | NR4A2 425/4885IKBKB 8/4885ALDH1A1 3293/4885 |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | NR4A2 417/4885IKBKB 8/4885ALDH1A1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.